Lung Cancer News and Research

Latest Lung Cancer News and Research

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Top medical organizations urge CMS to provide full Medicare coverage for LDCT screening

In a joint response to the Centers for Medicare & Medicaid Services (CMS) National Coverage and Analysis Group, the Lung Cancer Alliance, The Society of Thoracic Surgeons, American College of Radiology (ACR) and 38 other medical organizations called on CMS to quickly provide national Medicare coverage of low-dose computed tomography (LDCT) screening for patients at high risk for lung cancer.

17 Mar 2014

Findings reveal potential drug targets for small cell lung cancer

Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.

17 Mar 2014

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

A rule of electoral politics is that when a Democratic wave is building, the media broadcast it like a foregone conclusion. When a Republican wave is building, Beltway pundits are the last to admit it. After Tuesday's GOP win in a Florida special House election, even the press corps now agrees that Republicans are poised for major gains in November, assuming the GOP has the wit to exploit it (3/12).

14 Mar 2014

Consumers with canceled insurance exempted from individual mandate through 2016

Those who lost coverage because insurers canceled their plans have been given a hardship exemption through October 2016 from the requirement to have health insurance or pay a fine, Fox News reports. Other stories look at rising medical identity theft and the frustration of a cancer survivor who enrolled in a plan based on misinformation that her doctor was included in its network.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

13 Mar 2014

Roy Castle Lung Cancer Foundation funds two new projects to support research into lung cancer

The Roy Castle Lung Cancer Foundation has funded two new projects at the University of Liverpool which aim to improve survival rates for the UK's biggest cancer killer.

13 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Chronic smokers have altered emotional reactions when exposed to negative, positive images of tobacco

What if the use of a product influenced your perception of it, making you even more susceptible to its positive aspects and altering your understanding of its drawbacks? This is precisely what happens with cigarettes in chronic smokers, according to a recent study by the Institut universitaire en santé mentale de Montréal and University of Montreal.

11 Mar 2014

Tissue analysis near tumors holds promise for earlier detection, new treatments

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Institute.

9 Mar 2014

Research shows how patient experiences can be used to improve healthcare

A research project led by Oxford University is showing how patient experiences can be used to improve healthcare - not through targets and surveys, but by getting doctors, nurses and patients talking together about care on the ward.

6 Mar 2014

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Set of genes appear to predict which tumors can evade detection by immune system

Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.

5 Mar 2014

Researchers identify genes that appear to predict tumors that can evade detection by immune system

Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body’s immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.

5 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

Mcl-1 protein enables NSCLC to survive radiation and drug treatments

Researchers at the Translational Genomics Research Institute have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.

5 Mar 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

Trovagene reports net loss of $1 million for fourth quarter 2013

Top medical organizations urge CMS to provide full Medicare coverage for LDCT screening

Findings reveal potential drug targets for small cell lung cancer

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

Consumers with canceled insurance exempted from individual mandate through 2016

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Roy Castle Lung Cancer Foundation funds two new projects to support research into lung cancer

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Chronic smokers have altered emotional reactions when exposed to negative, positive images of tobacco

Tissue analysis near tumors holds promise for earlier detection, new treatments

Research shows how patient experiences can be used to improve healthcare

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Set of genes appear to predict which tumors can evade detection by immune system

Researchers identify genes that appear to predict tumors that can evade detection by immune system

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Mcl-1 protein enables NSCLC to survive radiation and drug treatments

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in